Test Price
2,800 AED✅ Home Collection Available
ITGB3 Gene Neonatal Alloimmune Thrombocytopenia Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
This NGS-based analysis of the ITGB3 gene delivers 99.9% diagnostic sensitivity for detecting pathogenic variants linked to neonatal alloimmune thrombocytopenia (NAIT). Validated under ISO 9001:2015 quality management, the test supports prenatal risk assessment and post‑natal management. Logistics include VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM–11 PM. Telephonic clinical guidance is provided post‑result, and direct billing verification is available via WhatsApp at +971 54 548 8731.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold‑Chain and VIP Mobile Phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This test uses Next Generation Sequencing (NGS) to analyze the ITGB3 gene at single‑nucleotide resolution, detecting all clinically relevant variants associated with NAIT. The assay runs on the Illumina NovaSeq 6000 platform with 100× coverage, providing definitive genotyping for families with a history of neonatal thrombocytopenia.
| Feature | Our NGS Test | Standard Serological Typing |
|---|---|---|
| Precision | Single‑nucleotide resolution, detects all rare variants | Detects only common platelet antigen mismatches |
| Methodology | Illumina NovaSeq NGS with 100× coverage | PCR‑SSP or ELISA phenotyping |
| Turnaround Time | 3–4 Weeks | 1–2 Weeks (limited scope) |
Physician Insight & Safety Protocols
Medication Advisory
Do not discontinue prescribed anticoagulants, antiplatelet therapy, or any medications without consulting your physician. This test is for genetic risk assessment and does not replace ongoing medical management.
Exclusion Criteria & Emergency Red Flags
- Neonates with active bleeding or thrombocytopenia requiring immediate transfusion: test may be deferred until stabilization.
- Genetic testing on cord blood is acceptable, but maternal contamination must be ruled out.
- If the mother has a history of NAIT, consult a fetal‑maternal medicine specialist before amniocentesis.
- ER Red Flags: Sudden petechiae, ecchymosis, or neurological signs in a newborn after birth—seek urgent hematology consult.
Patient FAQ & Clinical Guidance
1. What is the purpose of the ITGB3 gene test for neonatal alloimmune thrombocytopenia?
Direct Answer: This test identifies ITGB3 gene mutations causing NAIT to guide future pregnancy management. Detection enables prophylactic platelet‑matched transfusions and informed reproductive planning. Genetic counseling is recommended for all families with positive findings.
2. How is the sample collected and is home collection available in the UAE?
Direct Answer: Sample collection requires 2–3 mL of whole blood in an EDTA tube or a dried blood spot on an FTA card. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection is available daily from 8 AM to 11 PM across all Emirates via ISO‑certified phlebotomists.
3. How long do results take and what support is provided after testing?
Direct Answer: Results are reported within 3 to 4 weeks and include a complimentary telephonic clinical guidance session with a consultant medical geneticist to interpret findings. Secure WhatsApp support is available at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
This service operates under DHA Facility License No. 1143 and adheres to:
Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) — ensuring patient data confidentiality and security.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — governing electronic health data handling.
Federal Decree‑Law No. 4 of 2016 on Medical Liability — governing clinical safety and informed consent for genetic testing.
All specimens are processed in an ISO 9001:2015 certified laboratory with validated cold‑chain transport.
Clinical & Logistical Metadata
| Test Name | ITGB3 Gene Neonatal Alloimmune Thrombocytopenia NGS Analysis |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Dried Blood Spot (FTA Card) |
| Methodology Used | Next Generation Sequencing (NGS) – Illumina NovaSeq 6000, 100× coverage |
| ICD‑10‑CM Code | D69.51 (Neonatal alloimmune thrombocytopenia) |
| LOINC Code | 82857‑5 (ITGB3 gene mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians